Additional Resources | Daily COPD Medication

Take the test to see what impact COPD may be having on your life.¹⁰ Discuss your test score with your doctor or nurse.
Take the test
More information and support for people with COPD is available from:
Visit page
Visit page

Download

Any information provided on this website should be discussed with a healthcare professional and does not replace a healthcare professional’s advice.

Find out more about COPD:

Clicking on the above links will lead you to a third-party website, and GSK is not responsible for the content of that website. By clicking on the COPD Assessment Test link, you are leaving a GSK New Zealand website to a non-branded, international website developed by GSK.

References: 1. Anoro Ellipta Data Sheet, GSK New Zealand, available at www.medsafe.govt.nz 2. PHARMAC Pharmaceutical Schedule March 2024. Available at https://schedule.pharmac.govt.nz/2024/03/01/Schedule.pdf 3. Anoro Ellipta Consumer Medical Information, GSK New Zealand, available at www.medsafe.govt.nz 4. Lung Foundation Australia (2020). The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2020. 5. Grant AC International Society for Aerosols in Medicine 2015;28;474-85. 6. Town, I., Taylor, R., Garrett, J., & Patterson, J. (2003). The Burden of COPD in New Zealand. Available at https://bit.ly/3gsPc97 7. Anoro Ellipta Patient Information Leaflet, GSK New Zealand. October 2018. 8. Svedsater H. BMC Pulm Med;2013;13;1-14. 9. van der Palen J;npj Primary Care Respiratory Medicine;2016;26:16079;1-8. 10. COPD Assessment Test (CAT). Available at www.catestonline.org/ [Accessed September 2024].

Anoro Ellipta (umeclidinium (as bromide)/vilanterol (as trifenatate) inhaler, 62.5/25 mcg per dose) is a Prescription Medicine. Anoro Ellipta is used for long-term regular treatment to relieve symptoms in adults with Chronic Obstructive Pulmonary Disease (COPD). Anoro Ellipta is a fully funded medicine for patients with COPD – restrictions apply. Anoro Ellipta should not be used to relieve a sudden attack of breathlessness or wheezing. If you get this sort of attack, you must use a quick-acting (reliever) inhaler. Always carry your reliever inhaler. Do not discontinue Anoro Ellipta unless advised by your doctor. If symptoms continue or you have side effects, see your doctor, pharmacist or healthcare professional. Anoro Ellipta has risks and benefits. Use strictly as directed. For more information see Anoro Ellipta Consumer Medicine Information at www.medsafe.govt.nz. Normal doctor's charges apply. Ask your doctor if Anoro Ellipta is right for you. Trademarks are owned by or licensed to the GSK group of companies. ©2024 GSK group of companies or its licensor. Anoro Ellipta was developed in collaboration with Innoviva Inc. Marketed by GlaxoSmithKline NZ Limited, Auckland. Adverse events involving GlaxoSmithKline products should be reported to GSK Medical Information on 0800 808 500.
TAPS NP21643- PM-NZ-UCV-WCNT-200003. Date of Approval: 11 2024 Date of Expiry: 11 2026.

Where can I find out more about my COPD?

More information and support for people with COPD is available from:

Any information provided on this website should be discussed with a healthcare professional and does not replace a healthcare professional’s advice.